RICHMOND, VIRGINIA – NOV. 24, 2023

At Accorto, we strive to continuously look for ways to expand our capabilities to better serve our clients. Today we are excited to announce another key step on our continued growth trajectory in the medical device market segment by adding Dr. Kevin Lye in a Medical Advisor consultant role. Dr. Lye enhances Accorto’s depth of subject matter expertise, while also providing the ability to oversee certain clinical studies for regulatory application projects.

Dr. Lye has been associated with the biomedical industry for nearly twenty years, including receipt of competitive grant awards at the undergraduate, graduate, and post-graduate levels as well as a research fellowship at Yale University. Kevin earned his medical degree from the Wake Forest University School of Medicine and his MBA from Hawaii Pacific University with highest distinction and also served for over a decade as an assistant professor at the John A. Burns School of Medicine of the University of Hawai‘i.

Prior to assuming the role of Medical Advisor for Accorto Regulatory Solutions, Kevin served within the CMEI family of corporations as Chief Medical Officer and Strategy and Innovation Officer, and was VP of Medical Affairs for a global pharmaceutical corporation whilst engaging over eighty clinical trial sites worldwide for Phase II and III clinical studies.

Before this, Kevin was VP and Chief Medical Officer of a technology-holding company, leading it through an evaluation of its intellectual property portfolio including two pipeline products; he also spent over five years in the world of biomedical device development as the director of clinical research for a stem cell technology company, helping bring a stem cell isolation robot to defined markets and authoring first-in-man clinical trial protocols in orthopedic surgery, vascular surgery, cardiac surgery, plastic surgery, and other venues. He has a strong track record of interacting with FDA and USPTO, managing intellectual property registrations, coordinating contract research organizations, and securing business development transactions.